Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
LifeMD (LFMD)
NASDAQ:LFMD
Holding LFMD?
Track your performance easily
LFMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.99 - $12.88
Previous Close$5.04
Volume1.33M
Average Volume (3M)640.61K
Market Cap
$212.23M
Enterprise Value$207.60M
Total Cash (Recent Filing)$37.60M
Total Debt (Recent Filing)$25.14M
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Apr 08, 2025EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding43,312,117
10 Day Avg. Volume890,770
30 Day Avg. Volume640,611
Standard Deviation0.49
R-Squared0.02
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)-28.00
Price to Sales (P/S)1.10
Price to Cash Flow (P/CF)8.60
P/FCF Ratio15.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.08
Enterprise Value/Gross Profit1.55
Enterprise Value/Ebitda-20.88
Forecast
1Y Price Target
$12.00Price Target Upside138.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
LifeMD News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLifeMD shares appear inexpensive at approximately 5x the forecasted EBITDA for 2026 including full 'Weight Management' subscription revenue tied to compounded GLP-1 drugs.
Growth PotentialManagement reiterated high growth expectations over the next few years from newer programs ex-weight management, such as women's health and a new mail-order pharmacy.
Market DemandThe massive market demand for lower cost solutions for GLP-1s or compounded versions for them is high, benefiting both LifeMD and Hims.
Bears Say
Affordability IssuesManagement believes another major challenge for LFMD is patient affordability for the high price of branded GLP-1 drugs when insurance does not cover it.
Financial RisksInvestors are questioning the sustainability of revenue streams for LifeMD and other companies selling compounded forms of tirzepatide.
Regulatory ChallengesThe FDA's intention to take tirzepatide off the drug shortage list implies that compounding would no longer be allowed, posing a risk to LifeMD's revenue.
---
Ownership Overview
13.42% Insiders
8.76% Mutual Funds
12.07% Other Institutional Investors
57.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Ability to SellRisks related to the company’s ability to sell goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LFMD FAQ
What was LifeMD’s price range in the past 12 months?
LifeMD lowest stock price was $3.99 and its highest was $12.88 in the past 12 months.
What is LifeMD’s market cap?
Currently, no data Available
When is LifeMD’s upcoming earnings report date?
LifeMD’s upcoming earnings report date is Apr 08, 2025 which is in 107 days.
How were LifeMD’s earnings last quarter?
LifeMD released its earnings results on Nov 07, 2024. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.118 by -$0.022.
Is LifeMD overvalued?
According to Wall Street analysts LifeMD’s price is currently Undervalued.
Does LifeMD pay dividends?
LifeMD does not currently pay dividends.
What is LifeMD’s EPS estimate?
LifeMD’s EPS estimate is -$0.05.
How many shares outstanding does LifeMD have?
LifeMD has 43,312,120 shares outstanding.
What happened to LifeMD’s price movement after its last earnings report?
LifeMD reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.118. Following the earnings report the stock price went up 14.035%.
Which hedge fund is a major shareholder of LifeMD?
Among the largest hedge funds holding LifeMD’s share is Royce & Associates LLC. It holds LifeMD’s shares valued at 5M.
---
LifeMD Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (138.10% Upside)
$12.00 (138.10% Upside)
Blogger Sentiment
Bullish
LFMD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 352.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $162.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
78.32%
Trailing 12-Months
Company Description
LifeMD
Conversion Labs, Inc. engages in the manufacturing, distribution, and sale of natural immune support products containing proprietary yeast beta glucans. Its products are oral intake tablets and topical creams, and gels for skin application. It operates through the Finished Cosmetic Products and Nutraceutical and Cosmetic Additives segments. The company was founded in 1987 and is headquartered in New York, NY.
---
LFMD Company Deck
---
LFMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in LifeMD's telehealth business, with significant revenue growth, improved profitability, and strategic expansions in pharmacy operations. However, challenges remain with GLP-1 therapy coverage and maintaining growth in WorkSimpli's subscriber base. Despite these issues, the overall sentiment leans positive due to robust growth and financial results.Read More>---
LFMD Stock 12 Month Forecast
Average Price Target
$12.00
▲(138.10% Upside)
Technical Analysis
Best Analysts Covering LFMD
1 Year
1 Year Success Rate
9/30 ratings generated profit
1 Year Average Return
+17.63%
reiterated a buy rating 2 months ago
Copying David Larsen's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of +17.63% per trade.
---